Name: 글로벌 시장 동향
SKU: PH8500
Availability: InStock

보고서 요약(국문)

개요
전 세계 호산구 질환 시장은 2023년 1억 5천만 달러에 달했으며, 2024년부터 2031년까지 연평균 7.1%의 성장률을 보이며 2031년에는 2억 7천 8백만 달러에 이를 것으로 예상됩니다.
호산구 질환은 체내 호산구(백혈구의 일종)가 비정상적으로 증가하는 질환군입니다. 호산구 질환은 체내에서 호산구가 과다하게 생성되어 만성 염증과 조직 손상을 유발할 때 발생합니다.
호산구는 혈액과 비장, 림프절, 흉선, 위장관, 호흡기, 비뇨생식기계의 점막하 조직 등 특정 조직의 정상적인 구성 요소입니다. 정상적인 호산구 수는 혈액 1세제곱밀리미터당 0~450개입니다.

시장 동향: 성장 동력
연구 개발 증가 및 신약 승인
전 세계 호산구 질환 시장은 최근 다양한 연구 개발 덕분에 상당한 성장을 보였습니다. 호산구 질환은 일반적으로 병력, 임상 및 영상 소견을 바탕으로 진단됩니다. 또한, 호산구 질환 치료에 대한 첨단 연구 개발은 시장 성장을 가속화하는 데 기여하고 있습니다.
예를 들어, 2023년 2월 아스트라제네카와 암젠의 테즈스파이어(TEZSPIRE)는 중증 호산구 천식을 앓는 12세 이상 환자를 대상으로 사전 충전된 일회용 펜 형태의 자가 투여 방식으로 미국에서 승인되었습니다. 이 승인은 PATH-BRIDGE 1상 임상시험 결과를 포함한 PATHFINDER 임상시험 프로그램의 결과를 기반으로 합니다. 테즈스파이어는 중증 호산구 천식 환자를 위해 승인된 최초이자 유일한 생물학적 제제입니다.

또한, 주요 기업들의 파트너십 및 협력, 그리고 신약 승인과 같은 전략들이 이 시장을 견인할 것입니다. 예를 들어, 2022년 6월 FDA는 아토피 피부염, 천식, 비강 폴립을 동반한 만성 비부비동염(CRSwNP), 또는 호산구 식도염을 앓는 다양한 연령대의 환자들에게 사용할 수 있는 최초의 생물학적 제제인 듀픽센(듀필루맙)을 승인했습니다. 듀픽센은 인터루킨-4 및 인터루킨-13 경로의 신호 전달을 억제하는 완전 인간 단클론 항체입니다.
또한, 2022년 3월 아스트라제네카는 FDA로부터 벤랄리주맙에 대한 추가 생물학적 제제 허가 신청(sBLA)에 대한 보완 의견서(CRL)를 받았다고 발표했습니다. 벤랄리주맙은 중증 호산구 천식에 대한 추가 유지 치료제로 승인되었습니다.

제약 요인
높은 치료 비용, 질환 관련 합병증, 낮은 인식 및 진단율, 제한적인 보험 적용 정책, 그리고 제한된 치료 옵션 등의 요인이 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
전 세계 호산구 질환 시장은 유형, 치료법, 유통 채널 및 지역별로 세분화됩니다.
의약품 부문은 전 세계 호산구 질환 시장 점유율의 약 70.5%를 차지했습니다.
의약품 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 전 세계적으로 치료제 임상 시험이 증가함에 따라 호산구 질환 치료에 대한 수요가 증가하고 있습니다. clinicalTrials.gov에 따르면, 2022년 10월 스탠포드 대학교는 Incyte Corporation과 협력하여 호산구증가증후군 또는 원발성 호산구 질환 환자 치료를 위한 룩솔리티닙 임상 시험을 진행했습니다.
또한, 파트너십 및 협력, 인식 개선 프로그램과 같은 주요 기업들의 전략이 이 부문의 성장을 견인할 것입니다. 예를 들어, 2023년 3월 베이징 연합 의과대학 병원은 베이징 우정 병원과 공동으로 호산구증가증을 동반한 증식성 IgG4-RD 환자에서 바리시티닙과 글루코코르티코이드 병용 요법 및 글루코코르티코이드 단독 요법의 효능 및 안전성에 대한 중재 연구를 수행했습니다.
이 중재 연구는 경구용 약물인 프레드니솔론 0.6-0.8mg/kg을 4주 동안 매일 투여한 후 4개월에 걸쳐 점차 감량하여 중단하는 방식으로 진행되었습니다.
또한, 2022년 10월 콜로라도 어린이 병원 소화기 건강 연구소에서는 호산구 위장관 질환 환자를 대상으로 식도 스트링 테스트(EST)를 시행하여 위장관 호산구 질환 프로그램을 시작했습니다. 식도 스트링 테스트는 엔테로트래커(EnteroTracker)라는 간단한 채취 장치를 사용하여 성인과 어린이의 상부 위장관 검체를 채취합니다.

지리적 분석
북미는 전 세계 호산구 질환 시장 점유율의 약 43.3%를 차지했습니다.
호산구 천식, 호산구 위장염, 호산구 식도염과 같은 질환의 발생률 증가로 호산구증 치료제 수요가 증가함에 따라 북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다.
미국에서 호산구 식도염(EoE)은 식도를 손상시키고 기능을 저해하는 2형 염증으로 인해 발생하는 만성 진행성 질환입니다. 2024년 1월 현재 미국에서는 12세 미만 어린이 약 2만 1천 명이 승인되지 않은 치료법으로 EoE 치료를 받고 있습니다.

호산구 식도염을 앓는 어린이들은 기존 치료법이 있음에도 불구하고 상당한 의학적 미충족 수요를 안고 있으며, 미국에서는 12세 미만 어린이의 40%가 여전히 이 질환의 증상을 경험하고 있습니다.
또한, 이 지역의 주요 업체들이 인식 개선 프로그램을 도입하고 신약 승인을 추진함에 따라 시장 성장이 촉진될 것으로 예상됩니다. 예를 들어, 호산구 관련 질환을 위한 주요 옹호 단체인 미국 호산구 질환 파트너십(APFED)은 2023년 12월 뉴욕 타임스 스퀘어에서 두 번째 인식 개선 캠페인을 시작했습니다.
또한, 2024년 1월 미국 식품의약국(FDA)은 1세에서 11세 사이의 체중 15kg 이상 소아 호산구 식도염(EoE) 환자 치료를 위해 듀픽센트(듀필루맙)를 승인했습니다. 듀픽센트는 현재 미국에서 이러한 환자 치료를 위해 특별히 승인된 최초이자 유일한 약물입니다.

시장 세분화
유형별
• 호산구 식도염
• 호산구 위염
• 호산구 장염
• 호산구 대장염
• 호산구증가증후군
치료법별
• 약물
o 메폴리주맙
o 레슬리주맙
o 벤랄리주맙
o 듀필루나브
o 오말리주맙
o 이마티닙
o 기타
• 식이요법
• 확장술
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 한국
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
호산구 질환 시장의 주요 글로벌 기업으로는 Novartis A.G, GlaxoSmithKline Plc., Teva Pharmaceutical, Pfizer Inc., AstraZeneca, Sanofi S.A, Curia, LGM Pharma, Henan Lihua Pharmaceuticals Ltd., Hikma Pharmaceuticals 등이 있습니다.
주요 개발 사항
 2024년 2월, Takeda는 미국 식품의약국(FDA)이 11세 이상 호산구 식도염(EoE) 환자를 위한 최초이자 유일한 FDA 승인 경구 치료제인 EOHILIA(부데소니드 경구 현탁액)를 승인했다고 발표했습니다.

 2024년 2월, 뉴잉글랜드 의학 저널(New England Journal of Medicine)에 발표된 만다라(MANDARA) 3상 임상 데이터는 파센라(FASENRA)를 통해 호산구육아종성 혈관염(EGPA) 환자의 관해가 달성 가능한 목표임을 보여주었습니다.
 2022년 7월, 아레테이아 테라퓨틱스(Areteia Therapeutics, Inc.)는 호산구 천식 환자를 위한 최초의 경구 치료제 개발에 주력하는 임상 단계 바이오제약 회사로 출범을 발표했습니다. 아레테이아의 주요 후보 물질은 덱스프라미펙솔(dexpramipexole)로, 계열 최초의 경구용 호산구 성숙 억제제입니다.

보고서 구매 이유:

• 유형, 치료법, 유통 채널 및 지역별 글로벌 호산구 질환 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별하기 위해

• 전 세계 호산구 질환 시장의 모든 부문에 대한 다양한 데이터가 담긴 엑셀 데이터 시트

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 포함된 PDF 보고서

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공

전 세계 호산구 질환 시장 보고서는 약 62개의 표, 66개의 그림, 182페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
The global eosinophilic disorders market reached US$ 150 million in 2023 and is expected to reach US$ 278 million by 2031 growing with a CAGR of 7.1% during the forecast period 2024-2031.
Eosinophilic disorders are a group of conditions characterized by an abnormal increase in eosinophils, a type of white blood cell, in the body. Eosinophilic disorders occur when the body produces too many eosinophils, causing chronic inflammation and tissue damage.
Eosinophils are a normal component of the blood and certain tissues, such as the spleen, lymph nodes, thymus, and submucosal areas of the gastrointestinal, respiratory, and genitourinary tracts. Normal eosinophil counts range from 0 to 450 eosinophils per cubic millimeter of blood.
Market Dynamics: Drivers
Increasing Research & Developments and Approvals of New and Innovative Drugs
The global eosinophilic disorders market has witnessed significant growth due to various recent research and developments. Eosinophilic disorders are usually diagnosed based on medical history and clinical and imaging findings. Also, advanced research and developments in treating eosinophilic disorders help to accelerate market growth.
For instance, in February 2023, AstraZeneca and Amgen’s TEZSPIRE were approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe eosinophilic asthma. The approval is based on results from the PATHFINDER clinical trial program, which included results from the PATH-BRIDGE Phase I trial. EZSPIRE is the first and only biologic approved for patients with severe eosinophilic asthma.
Moreover, key player's strategies such as partnerships & collaboration, and drug approvals would drive this market. For instance, in June 2022, the FDA approved Dupixen (dupilumab) as the first biologic medicine for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), or eosinophilic esophagitis in different age populations. Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13 pathways.
Also, in March 2022, AstraZeneca that the FDA issued a complete response letter (CRL) regarding its supplemental Biologics License Application (sBLA) for benralizumab. Benralizumab is approved as an add-on maintenance treatment for severe eosinophilic asthma.
Restraints
Factors such as the high cost of the treatment, complications associated with the disorders, limited awareness & diagnosis among people, limited reimbursement policies, and limited treatment options are expected to hamper the market.
Segment Analysis
The global eosinophilic disorders market is segmented based on type, treatment, distribution channels, and region.
The medications segment accounted for approximately 70.5% of the global eosinophilic disorders market share
The medications segment is expected to hold the largest market share over the forecast period. The rising clinical trials of treatment drugs globally have contributed to the growing demand for eosinophilic disorders treatment. According to clinicalTrials.gov, in October 2022, Stanford University in collaboration with Incyte Corporation conducted a clinical trial on Ruxolitinib in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.
Moreover, key player strategies such as partnerships & collaborations, and awareness programs would drive this segment growth. For instance, in March 2023, Peking Union Medical College Hospital in collaboration with Beijing Friendship Hospital conducted an interventional study on the Efficacy and Safety of Baricitinib Combined With Glucocorticoid and Glucocorticoid Monotherapy in Proliferative IgG4-RD Patients with Eosinophilia.
The intervention involve the oral drug prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawn in 4 months.
Also, in October 2022, the Gastrointestinal Eosinophilic Disease Program launched at the Digestive Health Institute, Children's Hospital of Colorado by performing the Esophageal String Test (EST) on the eosinophilic gastrointestinal patients. The Esophageal String Test utilizes a simple collection device called EnteroTracker to collect upper gastrointestinal samples from adults and children.
Geographical Analysis
North America accounted for approximately 43.3% of the global eosinophilic disorders market share
North America region is expected to hold the largest market share over the forecast period owing to the rising incidence of conditions such as eosinophilic asthma, eosinophilic gastroenteritis, and eosinophilic esophagitis is driving the demand for eosinophilia therapeutics.
In the U.S., EoE (eosinophilic esophagitis) is a chronic, progressive disease driven by type 2 inflammation that damages the esophagus and impairs its function. In January 2024, approximately 21,000 children under the age of 12 in the U.S. are currently being treated for EoE with unapproved therapies.
Young children with eosinophilic esophagitis have significant unmet medical needs, despite existing treatment options, 40% of these children in the U.S. under the age of 12 continue to experience symptoms of this disease.
In addition, key players in this region introducing awareness programs and new drug approvals would drive this market growth. For instance, in December 2023, the American Partnership for Eosinophilic Disorders (APFED), a leading advocacy organization for eosinophil-associated disease, launched its second awareness campaign in the legendary Times Square in New York City.
Also, in January 2024, The U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients.
Market Segmentation
By Type
• Eosinophilic Esophagitis
• Eosinophilic Gastritis
• Eosinophilic Enteritis
• Eosinophilic Colitis
• Hypereosinophilic Syndrome
By Treatment
• Medications
o Mepolizumab
o Reslizumab
o Benralizumab
o Dupilunab
o Omalizumab
o Imatinib
o Others
• Dietary Therapy
• Dilation
• Others
By Distribution Channels
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the eosinophilic disorders market include Novartis A.G, GlaxoSmithKline Plc., Teva Pharmaceutical, Pfizer Inc., AstraZeneca, Sanofi S.A, Curia, LGM Pharma, Henan Lihua Pharmaceuticals Ltd., and Hikma Pharmaceuticals among others.
Key Developments
 In February 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).
 In February 2024, MANDARA Phase III data published in the New England Journal of Medicine showed remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
 In July 2022, Areteia Therapeutics, Inc. announced its launch as a clinical-stage biopharmaceutical company focused on putting asthma patients in better control of their disease with the first potential oral therapy for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole which is a first-in-class oral eosinophil maturation inhibitor.
Why Purchase the Report?
• To visualize the global eosinophilic disorders market segmentation based on type, treatment, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global eosinophilic disorders market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global eosinophilic disorders market report would provide approximately 62 tables, 66 figures, and 182 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Distribution Channels
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Research & Developments and Approvals of New and Innovative Drugs
4.1.1.2. Increasing Prevalence of Eosinophilic Disorders
4.1.2. Restraints
4.1.2.1. High Cost of the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Eosinophilic Esophagitis
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Eosinophilic Gastritis
6.4. Eosinophilic Enteritis
6.5. Eosinophilic Colitis
6.6. Hypereosinophilic Syndrome
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Medications
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.2.1. Mepolizumab
7.2.2.2. Reslizumab
7.2.2.3. Benralizumab
7.2.2.4. Dupilunab
7.2.2.5. Omalizumab
7.2.2.6. Imatinib
7.2.2.7. Others
7.3. Dietary Therapy
7.4. Dilation
7.5. Others
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacy
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacy
8.4. Online Pharmacy
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Product Benchmarking
10.3. Company Share Analysis
10.4. Key Developments and Strategies
11. Company Profiles
11.1. Novartis A.G *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. GlaxoSmithKline Plc.
11.3. Teva Pharmaceutical
11.4. Pfizer Inc.
11.5. AstraZeneca
11.6. Sanofi S.A
11.7. Curia
11.8. LGM Pharma
11.9. Henan Lihua Pharmaceuticals Ltd.
11.10. Hikma Pharmaceuticals
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Novartis A.G, 4.	Key Developments, GlaxoSmithKline Plc., Teva Pharmaceutical, Pfizer Inc., AstraZeneca, Sanofi S.A, Curia, LGM Pharma, Henan Lihua Pharmaceuticals Ltd., Hikma Pharmaceuticals

표 목록 (Tables)

List of Tables

Table 1 Global Eosinophilic Disorders Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Eosinophilic Disorders Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Eosinophilic Disorders Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Eosinophilic Disorders Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Eosinophilic Disorders Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Eosinophilic Disorders Market Value, By Type, 2022-2031 (US$ Million)

Table 7 Global Eosinophilic Disorders Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Eosinophilic Disorders Market Value, By Treatment, 2022-2031 (US$ Million)

Table 9 Global Eosinophilic Disorders Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Eosinophilic Disorders Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Eosinophilic Disorders Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Eosinophilic Disorders Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Eosinophilic Disorders Market Value, By Type, 2022-2031 (US$ Million)

Table 14 North America Eosinophilic Disorders Market Value, By Treatment, 2022-2031 (US$ Million)

Table 15 North America Eosinophilic Disorders Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Eosinophilic Disorders Market Value, By Country, 2022-2031 (US$ Million)

Table 17 Asia-Pacific Eosinophilic Disorders Market Value, By Type, 2022-2031 (US$ Million)

Table 18 Asia-Pacific Eosinophilic Disorders Market Value, By Treatment, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Eosinophilic Disorders Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Eosinophilic Disorders Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Eosinophilic Disorders Market Value, By Type, 2022-2031 (US$ Million)

Table 22 Europe Eosinophilic Disorders Market Value, By Treatment, 2022-2031 (US$ Million)

Table 23 Europe Eosinophilic Disorders Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Eosinophilic Disorders Market Value, By Country, 2022-2031 (US$ Million)

Table 25 South America Eosinophilic Disorders Market Value, By Type, 2022-2031 (US$ Million)

Table 26 South America Eosinophilic Disorders Market Value, By Treatment, 2022-2031 (US$ Million)

Table 27 South America Eosinophilic Disorders Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 South America Eosinophilic Disorders Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East and Africa Eosinophilic Disorders Market Value, By Type, 2022-2031 (US$ Million)

Table 30 Middle East and Africa Eosinophilic Disorders Market Value, By Treatment, 2022-2031 (US$ Million)

Table 31 Middle East and Africa Eosinophilic Disorders Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 Middle East and Africa Eosinophilic Disorders Market Value, By Country, 2022-2031 (US$ Million)

Table 33 Novartis A.G: Overview

Table 34 Novartis A.G: Product Portfolio

Table 35 Novartis A.G: Key Developments

Table 36 GlaxoSmithKline Plc.: Overview

Table 37 GlaxoSmithKline Plc.: Product Portfolio

Table 38 GlaxoSmithKline Plc.: Key Developments

Table 39 Teva Pharmaceutical: Overview

Table 40 Teva Pharmaceutical: Product Portfolio

Table 41 Teva Pharmaceutical: Key Developments

Table 42 Pfizer Inc.: Overview

Table 43 Pfizer Inc.: Product Portfolio

Table 44 Pfizer Inc.: Key Developments

Table 45 AstraZeneca: Overview

Table 46 AstraZeneca: Product Portfolio

Table 47 AstraZeneca: Key Developments

Table 48 Sanofi S.A: Overview

Table 49 Sanofi S.A: Product Portfolio

Table 50 Sanofi S.A: Key Developments

Table 51 Curia: Overview

Table 52 Curia: Product Portfolio

Table 53 Curia: Key Developments

Table 54 LGM Pharma: Overview

Table 55 LGM Pharma: Product Portfolio

Table 56 LGM Pharma: Key Developments

Table 57 Henan Lihua Pharmaceuticals Ltd.: Overview

Table 58 Henan Lihua Pharmaceuticals Ltd.: Product Portfolio

Table 59 Henan Lihua Pharmaceuticals Ltd.: Key Developments

Table 60 Hikma Pharmaceuticals: Overview

Table 61 Hikma Pharmaceuticals: Product Portfolio

Table 62 Hikma Pharmaceuticals: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 2 Global Eosinophilic Disorders Market Share, By Type, 2023 & 2031 (%)

Figure 3 Global Eosinophilic Disorders Market Share, By Treatment, 2023 & 2031 (%)

Figure 4 Global Eosinophilic Disorders Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 5 Global Eosinophilic Disorders Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Eosinophilic Disorders Market Y-o-Y Growth, By Type, 2023-2031 (%)

Figure 7 Eosinophilic Esophagitis Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 8 Eosinophilic Gastritis Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 9 Eosinophilic Enteritis Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 10 Eosinophilic Colitis Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 11 Hypereosinophilic Syndrome Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 12 Others Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 13 Neural Bionics Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 14 Others Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 15 Global Eosinophilic Disorders Market Y-o-Y Growth, By Treatment, 2023-2031 (%)

Figure 16 Medications Treatment in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 17 Mepolizumab Treatment in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 18 Reslizumab Treatment in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 19 Benralizumab Treatment in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 20 Dupilunab Treatment in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 21 Omalizumab Treatment in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 22 Imatinib Treatment in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 23 Others Treatment in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 24 Dietary Therapy Treatment in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 25 Dilation Treatment in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 26 Others Treatment in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 27 Global Eosinophilic Disorders Market Y-o-Y Growth, By Distribution Channel, 2023-2031 (%)

Figure 28 Hospital Pharmacies Distribution Channel in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 29 Retail Pharmacies Distribution Channel in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 30 Online Pharmacies Distribution Channel in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 31 Others Distribution Channel in Global Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 32 Global Eosinophilic Disorders Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 33 North America Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 34 North America Eosinophilic Disorders Market Share, By Type, 2023 & 2031 (%)

Figure 35 North America Eosinophilic Disorders Market Share, By Treatment, 2023 & 2031 (%)

Figure 36 North America Eosinophilic Disorders Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 37 North America Eosinophilic Disorders Market Share, By Country, 2023 & 2031 (%)

Figure 38 Asia-Pacific Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 39 Asia-Pacific Eosinophilic Disorders Market Share, By Type, 2023 & 2031 (%)

Figure 40 Asia-Pacific Eosinophilic Disorders Market Share, By Treatment, 2023 & 2031 (%)

Figure 41 Asia-Pacific Eosinophilic Disorders Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 42 Asia-Pacific Eosinophilic Disorders Market Share, By Country, 2023 & 2031 (%)

Figure 43 Europe Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 44 Europe Eosinophilic Disorders Market Share, By Type, 2023 & 2031 (%)

Figure 45 Europe Eosinophilic Disorders Market Share, By Treatment, 2023 & 2031 (%)

Figure 46 Europe Eosinophilic Disorders Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 47 Europe Eosinophilic Disorders Market Share, By Country, 2023 & 2031 (%)

Figure 48 South America Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 49 South America Eosinophilic Disorders Market Share, By Type, 2023 & 2031 (%)

Figure 50 South America Eosinophilic Disorders Market Share, By Treatment, 2023 & 2031 (%)

Figure 51 South America Eosinophilic Disorders Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 52 South America Eosinophilic Disorders Market Share, By Country, 2023 & 2031 (%)

Figure 53 Middle East and Africa Eosinophilic Disorders Market Value, 2022-2031 (US$ Million)

Figure 54 Middle East and Africa Eosinophilic Disorders Market Share, By Type, 2023 & 2031 (%)

Figure 55 Middle East and Africa Eosinophilic Disorders Market Share, By Treatment, 2023 & 2031 (%)

Figure 56 Middle East and Africa Eosinophilic Disorders Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 57 Novartis A.G: Financials

Figure 58 GlaxoSmithKline Plc.: Financials

Figure 59 Teva Pharmaceutical: Financials

Figure 60 Pfizer Inc.: Financials

Figure 61 AstraZeneca: Financials

Figure 62 Sanofi S.A: Financials

Figure 63 Curia: Financials

Figure 64 LGM Pharma: Financials

Figure 65 Henan Lihua Pharmaceuticals Ltd.: Financials

Figure 66 Hikma Pharmaceuticals: Financials

세계 호산구 질환 시장 – 2024-2031년

Global Eosinophilic Disorder Market - 2024-2031